published meta-analysis   sensitivity analysis   studies

darunavir cobicistat in COVID-19 - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsJun C, 2020 1.00 [0.02; 53.89] 1.00[0.02; 53.89]Jun C, 202010%30seriousnot evaluable deathsdetailed resultsJun C, 2020 1.00 [0.02; 53.89] 1.00[0.02; 53.89]Jun C, 202010%30seriousnot evaluable clinical deteriorationdetailed resultsJun C, 2020 2.07 [0.06; 66.79] 2.07[0.06; 66.79]Jun C, 202010%30seriousnot evaluable mechanical ventilationdetailed resultsJun C, 2020 2.07 [0.06; 66.79] 2.07[0.06; 66.79]Jun C, 202010%30seriousnot evaluable viral clearance detailed resultsJun C, 2020 0.82 [0.36; 1.87] 0.82[0.36; 1.87]Jun C, 202010%30seriousnot evaluable viral clearance (time to event analysis only)detailed resultsJun C, 2020 0.82 [0.36; 1.87] 0.82[0.36; 1.87]Jun C, 202010%30seriousnot evaluable viral clearance by day 7detailed resultsJun C, 2020 0.58 [0.14; 2.48] 0.58[0.14; 2.48]Jun C, 202010%30seriousnot evaluable0.25.01.0relative treatment effectwww.metaEvidence.org2021-06-19 20:01 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 87,95,94,90,91,97 - treatments: 512,515 - roots T: 290